Annual Meeting, American Society of Hematology

Dozens of presentations advance multiple myeloma research at the 2024 American Society for Hematology (ASH) meeting
Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center,
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting,
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 weeksDurable clinical responses were associated with improvements in patient-reported measures of fatigue in MDS patients early,
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
(NASDAQ: NEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting,
BioPharma Dive1d
ASH24: Leukemia drug sequencing, sickle cell questions and a new kind of CAR-T
Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...
STAT3d
Pfizer’s abrupt withdrawal of sickle cell drug Oxbryta called ‘tone deaf’ at ASH conference
SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a ...
sicklecellanemianews35m
Most patients free of vaso-occlusive crises for years after Casgevy dose
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
ReAlta Presenting New Results in aGVHD at American Society of Hematology 2024
By Karen Roman ReAlta Life Sciences said it is presenting new data at the American Society of Hematology (ASH) Annual Meeting ...
Morningstar6d
BostonGene Announces Twelve Abstracts Selected for Presentation at the 66th American Society of Hematology Annual Meeting & Exposition
today announced the selection of 10 abstracts for poster presentations and two abstracts for online publication at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition ...